

Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno

Vargas, C., Espinoza, M. A., Giglio, A., & Soza, A. (2017). Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno. Value in health regional issues, 14, 28-32.

Abstract:

Objectives

To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile.

Methods

A Chilean HC1b patients cohort was modelled using local prevalence and incidence data. Two scenarios were built and compared, one where all patients receive Peginterferon/Ribavirin (PR) and another where all patients are treated with DCV/ASV. The analysis was conducted from the perspective of the public health system of Chile assuming 100% reimbursement and a time horizon of 5 years. Costs associated with drug treatment, adverse events, other relevant resources and costs associated with disease complications were used.

Results

At a total DCV/ASV treatment price of USD \$55,039, an additional USD \$65,6MM are required during the first year (prevalent cases) equivalent to 0.71% of the 2015 national health budget. From year 2 (incident cases), an additional USD \$12,3MM are needed (0.13% of the 2015 health budget). A price reduction of 33% (USD \$36,693), requires an additional USD \$38,2MM the first year and USD \$7,16MM from the second year (0.11% and 0.6% of the health budget). If the treatment price is reduced further (USD \$18,347), an additional USD \$10,9MM are required for the first year and USD \$2,03MM from the second year (0.3% and 0.057% of the 2015 health budget).

Conclusion

The impact on the health budget ranges between 0.3% and 0.71% the first year and decreases to less than 0.15% from the second year considering the price assessed price range.

Keywords:

Creado: Viernes, 11 de Diciembre, 2020